The Impact of Vitamin D 3 Supplementation to Topiramate Therapy on Pediatric Migraine Prophylaxis

• Published in: Journal of child neurology Vol. 37; no. 10-11; p. 833
• Main Authors: Kotb Elmala, Moustafa, Suliman, Hany Abdelaziz, Al-Shokary, Ashraf Hamed, Ibrahim, Asmaa Obada, Kamal, Naglaa M, Elshorbagy, Hatem Hamed, Nasef, Khaled Amin, El Din Fathallah, Mohamed Gamal
• Format: Journal Article
• Language: English
• Published: United States 01.10.2022
• Subjects: Adolescent; Anticonvulsants - therapeutic use; Child; Child, Preschool; Cholecalciferol - adverse effects; Dietary Supplements; Double-Blind Method; Fructose - adverse effects; Humans; Migraine Disorders - drug therapy; Migraine Disorders - prevention & control; Prospective Studies; Topiramate - therapeutic use; Treatment Outcome; Vitamin D - therapeutic use; migraine; prophylaxis; vitamin D3 supplementation; pediatric; topiramate
• ISSN: 1708-8283
• DOI: 10.1177/08830738221092882

There is still a need for more studies to evaluate the role of vitamin D in pediatric migraine prophylaxis. We aimed to evaluate the effects and safety of vitamin D supplementation to topiramate on pediatric migraine. A double-blinded prospective clinical trial was conducted on 5- to 14-year-old children with migraine. They were randomly assigned in a 1:1 ratio into 2 groups, one with vitamin D supplementation (the supplementation group) and the other without vitamin D supplementation (the placebo group). The supplementation group received topiramate plus one 5000-IU dose of vitamin D daily for 4 months. The placebo group received topiramate with a placebo capsule without any effective substances. The primary outcomes were a monthly frequency of headache attacks, a good response to intervention, and reduction in migraine severity, duration, and disability before and after treatment. Fifty-six children completed the trial. Vitamin D supplementation to topiramate was more effective than the placebo group in the reduction of monthly frequency (6231.31 vs 9792.24 times,  = .01) and disability score for migraines (17 566.43 vs 25 187.65,  = .04). A good response was observed in 76.13% of patients in the vitamin D supplementation group and 53.5% of patients in the placebo group, and vitamin D supplementation was significantly more effective than placebo (  = .01). Side effects were observed in 13.3% and 20% of the intervention group and placebo groups, respectively,  = .5. Vitamin D supplementation in pediatric migraine prophylaxis could be a well-tolerated, safe, and effective strategy.